Sponsors

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women’s health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com

A global pharmaceutical company. Our purpose is to push the boundaries of science to deliver life-changing medicines. The best way we can help patients is to be science-led and share this passion with the scientific, healthcare and business communities.

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions and post-approval services.

Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of more than 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally.

Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and Twitter @Fortrea.

ICON is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,150 employees in 113 locations in 53 countries as of September 30, 2022. For further information about ICON, visit: www.iconplc.com.

Panthera is the UK’s largest independent Site Management Organisation (SMO), specialising in patient recruitment and the delivery of clinical trials through its network of seven dedicated research clinics across the UK. Working in partnership with leading CROs and pharmaceutical companies, Panthera provides rapid, reliable access to millions of potential participants, enabling the recruitment of thousands of patients at speed.

Dr Ian Smith MBE, one of Panthera’s founders, pioneered the SMO model. Since its launch in 2019, Panthera has redefined clinical trial delivery in the UK. In just a few years, it has become the market leader, supporting ten of the world’s top twelve pharmaceutical companies and seven of the leading CROs.

Panthera is recognised for its ability to deliver high-quality trials quickly and efficiently – providing sponsors with certainty, accelerating study timelines, and streamlining the path to commercialisation.

In August 2025, Panthera secured investment from leading private equity investor LDC to support its continued expansion and enhance its clinical capabilities.

Performance and Achievements:

• Offers the widest range of clinical trial therapy areas of any UK SMO, covering Alzheimer’s, oncology, cardiovascular disease, metabolic studies, respiratory conditions, vaccines, rheumatology/immunology, neurology, and more.

• Consistently the first sites to pre-screen, screen and randomise patients in the UK, EU and sometimes Globally due to exceptional start up timelines.

• Ranked top global recruiter in four studies and top UK recruiter in six more over the past two years (Often contributing 50%+ of the UK participants in therapy areas such as CVD, Vaccines and CNS)

• Achieving Alliance/strategic partnership level with most top tier CRO organisations.

• Has built the largest and most digitally advanced patient database and study access model ever seen in the UK driving active engagements with over 300,000 patient candidates.

Panthera’s success is built on its rapid study start-up capabilities, broad patient access, and the expertise of its experienced Principal Investigators and management team – ensuring high-quality research and a collaborative approach to every partnership.

For more information, visit www.panthera-bio.com

As a leading global clinical research organization (CRO), Parexel supports the development of innovative new medicines to improve the health of patients. We provide services to help life sciences and biopharmaceutical clients everywhere transform scientific discoveries into new treatments. From decentralized clinical trials to regulatory consulting services and leveraging real-world insights, our therapeutic, technical, and functional ability is underpinned by a patient-first culture embedded in our DNA. Our employees have a deep conviction in what we do, and together with our customers, we are shaping the next generation of therapies, one patient at a time. What we do, we do With Heart™.

PPD is delighted to sponsor PharmaTimes International Clinical Researcher of the Year 2023.

PPD is a leading global contract research organisation providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organisations. With locations in 46 countries and more than 26,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health.